Our Mission
Mapping a New Universe of Medicine
Octant merges next-generation biology, chemistry, and computation to engineer precision medicines that push past the boundaries of traditional drug discovery.
Next-generation small molecule therapeutics
Drugging the cellular mechanisms that cause disease
Most drug programs focus on binding molecules to a purified “target” protein, hoping that binding will drive a desired downstream function. Octant engineers biology and chemistry at massive scales to modulate the function itself, targeting complex cellular mechanisms that drive disease. We've focused these efforts internally on correcting diseases of protein misfolding and mistrafficking.
Our Pipeline
See how we're harnessing our platform to build therapies that deliver relief to patients.
OCT-980: A New Clinical Approach for Retinitis Pigmentosa
Retinitis Pigmentosa (RP) is a group of inherited retinal disorders that cause progressive vision loss and can lead to blindness. Rhodopsin-associated autosomal dominant RP (RHO-adRP) is among the most severe and prevalent forms, yet no treatment options exist for the thousands of individuals affected by this disease.
OCT-980 is a first-in-disease oral small molecule designed to correct protein misfolding for rhodopsin gene mutations, the root cause of RHO-adRP. By restoring protein function, OCT-980 aims to improve low-light vision and halt disease progression. Preclinical studies show strong efficacy and a favorable safety profile, supporting advancement into clinical trials in early 2026.
At Octant, we're redefining what's possible in precision medicine by targeting the root causes of genetic diseases and bringing transformative therapies from discovery to the clinic.
Working at Octant
Of and by technologists.
For patients.
We are a group of technologists and builders charting new approaches to drug discovery. We combine new technologies to find simple and elegant solutions to complex problems. Scientists, engineers and operators - we are all working together to build a new type of company.
About UsContact us
If you are passionate about next-generation drug discovery, we’d love to hear from you.
ahoy@octant.bio